Anti-inflammatory agent 52 (compound 7c) is an orally active, selective COX-2 inhibitor with demonstrated anti-HT29 metastatic activity, causing periodic arrest in the S phase and G2/M phase. This agent exhibits moderate anti-inflammatory efficacy alongside a notable safety profile. Additionally, it possesses the uncommon capability of inhibiting tumor development in a mouse model, indicative of anti-cancer properties [1].